Literature DB >> 21474210

[Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update].

Jesús Fortún1, Jordi Carratalá, Joan Gavaldá, Manuel Lizasoain, Miguel Salavert, Rafael de la Cámara, Marcio Borges, Carlos Cervera, José Garnacho, Álvaro Lassaleta, Carlos Lumbreras, Miguel Ángel Sanz, José T Ramos, Julián Torre-Cisneros, José M Aguado, Manuel Cuenca-Estrella.   

Abstract

The guidelines on the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) are presented. These recommendations are focused on four clinical categories: oncology-haematology patients, solid organ transplant recipients, patients admitted to intensive care units, and children. An extensive review is made of therapeutical advances and scientific evidence in these settings. These guidelines have been prepared according the SEIMC consensus rules by a working group composed of specialists in infectious diseases, clinical microbiology, critical care medicine, paediatrics and oncology-haematology. Specific recommendations on the prevention of fungal infections in these patients are included.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474210     DOI: 10.1016/j.eimc.2011.01.010

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  8 in total

1.  The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.

Authors:  Ana Cecilia Mesa-Arango; Nuria Trevijano-Contador; Elvira Román; Ruth Sánchez-Fresneda; Celia Casas; Enrique Herrero; Juan Carlos Argüelles; Jesús Pla; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.

Authors:  L Bernal-Martínez; L Alcazar Fuoli; B Miguel-Revilla; A Carvalho; M S Cuétara Garcia; J Garcia-Rodriguez; C Cunha; E Gómez-García de la Pedrosa; A Gomez-Lopez
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Levels of evidence supporting clinical practice guidelines on invasive aspergillosis.

Authors:  Sofía Tejada; Laura Campogiani; João Ferreira-Coimbra; Stijn Blot; Jordi Rello
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-03       Impact factor: 3.267

4.  Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.

Authors:  Helmut Ostermann; Carlos Solano; Isidro Jarque; Carolina Garcia-Vidal; Xin Gao; Jon Andoni Barrueta; Marina De Salas-Cansado; Jennifer Stephens; Mei Xue; Bertram Weber; Claudie Charbonneau
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-24       Impact factor: 2.483

5.  Preemptive Antifungal Therapy for Febrile Neutropenic Hematological Malignancy Patients in China.

Authors:  Wei Yuan; Jinhai Ren; Xiaonan Guo; Xiaoling Guo; Shengxin Cai
Journal:  Med Sci Monit       Date:  2016-11-07

6.  [Nosocomial infection in patients receiving a solid organ transplant or haematopoietic stem cell transplant].

Authors:  Asunción Moreno Camacho; Isabel Ruiz Camps
Journal:  Enferm Infecc Microbiol Clin       Date:  2014-06-18       Impact factor: 1.731

Review 7.  Clinical practice update of antifungal prophylaxis in immunocompromised children.

Authors:  J T Ramos; C A Romero; S Belda; F J Candel; B Carazo Gallego; A Fernández-Polo; L Ferreras Antolín; C Garrido Colino; M L Navarro; O Nef; P Olbright; E Rincón-López; J Ruiz Contreras; P Soler-Palacín
Journal:  Rev Esp Quimioter       Date:  2019-09-11       Impact factor: 1.553

8.  Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol.

Authors:  Jaime Monserrat Villatoro; Irene García García; David Bueno; Rafael de la Cámara; Miriam Estébanez; Ana López de la Guía; Francisco Abad-Santos; Cristina Antón; Gina Mejía; María José Otero; Elena Ramírez García; Jesús Frías Iniesta; Antonio Carcas; Alberto M Borobia
Journal:  BMJ Open       Date:  2020-10-01       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.